Reliance Bulk Drugs And Formulations Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 3.00 Cr
- Company Age 38 Year, 11 Months
- Last Filing with ROC 31 Mar 2012
About Reliance Bulk Drugs And Formulations
Reliance Bulk Drugs And Formulations Limited (RBDAFL) is a Public Limited Indian Non-Government Company incorporated in India on 12 March 1986 and has a history of 38 years and 11 months. Its registered office is in Himachal Prasdesh, Himachal Pradesh.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2012. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mukesh Gakhar, Vijay Chawla, and Gaurav Sharma serve as directors at the Company.
Company Details
- Location Himachal Prasdesh, Himachal Pradesh
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230HP1986PLC006738
- Company No.
006738
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Mar 1986
- Date of AGM
29 Sep 2012
- Date of Balance Sheet
31 Mar 2012
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Reliance Bulk Drugs And Formulations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Gakhar  | Director | 11-Jan-2010 | Current |
| Vijay Chawla | Director | 10-Apr-2013 | Current |
| Gaurav Sharma | Director | 01-Oct-2014 | Current |
Financial Performance of Reliance Bulk Drugs And Formulations.
Enhance accessibility to Reliance Bulk Drugs And Formulations's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Reliance Bulk Drugs And Formulations?
Unlock access to Reliance Bulk Drugs And Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Reliance Drugs And Formulations Pvt LtdVijay Chawla is a mutual person
- Luxuriun Leathers Private Limited
Gaurav Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Reliance Bulk Drugs And Formulations?
Unlock and access historical data on people associated with Reliance Bulk Drugs And Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reliance Bulk Drugs And Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reliance Bulk Drugs And Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
